New drug duo tested to fight disfiguring tumors
NCT ID NCT06502171
Summary
This early-stage study is testing whether combining two existing cancer drugs, cabozantinib and selumetinib, is safe and effective for shrinking painful and disfiguring tumors (plexiform neurofibromas) in people aged 16 and older with neurofibromatosis type 1 (NF1). The research will first find the safest dose of the drug combination and then see how well it reduces tumor size. The goal is to offer a new treatment option for tumors that are hard to treat with surgery or other therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROFIBROMATOSIS 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 34294, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.